loader from loading.io

ANA Investigates Biomarkers for Alzheimer's Disease

ANA Investigates

Release Date: 06/15/2020

ANA Investigates Updates in Autoimmune Encephalitis, part 1, diagnostics show art ANA Investigates Updates in Autoimmune Encephalitis, part 1, diagnostics

ANA Investigates

On today's episode, Dr. Adeline Goss interviews Dr. Andrew McKeon on updates on diagnostics for part one of a two-part series on autoimmune encephalitis. Series 3, Episode 8. Featuring: Guest: Andrew McKeon, M.B., B.Ch., M.D., Mayo Clinic College of Medicine and Science Interviewer/Producer: Adeline Goss, MD, Highland Hospital Disclosures: Dr. McKeon disclosed that he is a consultant for Johnson & Roche Genentech; and receives royalties from Euroimmun

info_outline
ANA Investigates TIA show art ANA Investigates TIA

ANA Investigates

On today's episode, we discuss the term "TIA" and the current debate as it pertains to advances in stroke diagnostics that have led some to propose that we retire the term. Series 3, Episode 7. Featuring: Guest: Clay Johnston, MD, PhD, The University of Texas at Austin Interviewer/Producer: Megan Richie, MD, UCSF Disclosures: Dr. Johnston disclosed research support from AstraZeneca for the THALES trial.

info_outline
ANA Investigates Neurobiology of Burnout show art ANA Investigates Neurobiology of Burnout

ANA Investigates

Burnt out by talking about burnout? Please join us for a podcast with Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University, to investigate what goes on in the brain that leads to burnout and how this can direct our efforts to reduce burnout. Series 3, Episode 6. Featuring: Guest: Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University - Interviewer/Producer: Dr. Amanda Jagolino-Cole of the McGovern Medical at the University of Texas Health Science Center in Houston Dr. Arnsten provided additional resources, and these may be found on the ANA...

info_outline
ANA Investigates Biomarkers for Alzheimer's Disease show art ANA Investigates Biomarkers for Alzheimer's Disease

ANA Investigates

On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease. We know that amyloid beta and tau protein deposit long before patients with Alzheimer’s develop symptoms. If we could use biomarkers to detect this pathology early, and treat patients early, could we prevent the progression to dementia? Our guests today are leaders in the development of biomarkers for Alzheimer’s disease - Dr. Suzanne Schindler, Associate Professor of Neurology at Washington University in St. Louis and Dr. Gil Rabinovici, Professor of Neurology and Radiology at the University of...

info_outline
ANA Investigates Curing Coma show art ANA Investigates Curing Coma

ANA Investigates

Can coma be “cured”? On this podcast, we talk to Dr. Claude Hemphill and Dr. Romer Geocadin of the Curing Coma Campaign. Series 3, Episode 4 Featuring: Guests: Romer Geocadin, MD, Johns Hopkins University & Claude Hemphill, MD, University of California San Francisco Interviewer/Producer: Dr. Adeline Goss Below are articles the guests of this podcast wished to share with the listeners: Early Thalamocortical Reperfusion Leads to Neurologic Recovery in a Rodent Cardiac Arrest Model: https://doi.org/10.1007/s12028-021-01432-9 Proceedings of the First Curing Coma Campaign NIH...

info_outline
ANA Investigates Basilar Artery Stroke show art ANA Investigates Basilar Artery Stroke

ANA Investigates

Treatment of stroke has changed dramatically in the past decade, with the advent of perfusion imaging and an expanded time window for mechanical thrombectomy. Thrombectomy is now standard of care for eligible patients. But while data clearly supports the use of thrombectomy for certain patients with anterior circulation strokes, the benefit of thrombectomy for patients with basilar artery occlusions remains unproven. Today we’ll talk to a vascular neurologist and a neurointerventional surgeon who are trying to better define which patients with basilar artery occlusion may benefit from...

info_outline
ANA Investigates FND show art ANA Investigates FND

ANA Investigates

On today’s show we’ll focus on functional neurological disorder, or FND -- a wide range of conditions including non-epileptic seizures and functional weakness, dystonia and tremor. These conditions are common and can cause serious disability. But what are these conditions, exactly? What have functional neuroimaging and other tools taught us about their pathophysiology, diagnosis, and treatment? Series 3, Episode 2 Featuring: - Guest: Dr. Sara Finkelstein, neurologist and specialist in functional neurological disorder at Massachusetts General Hospital - Interviewer/Producer: Dr. Adeline...

info_outline
ANA Investigates Neurostimulation show art ANA Investigates Neurostimulation

ANA Investigates

Some patients with medically refractory epilepsy are offered surgeries to implant devices that electrically stimulate the nervous system and actually modulate neural networks over time. On this episode of ANA Investigates, Dr. Vikram Rao of the UCSF Weill Institute for Neurosciences discusses how these neurostimulation devices can reduce seizure burden, along with a range of other potential benefits.‌ Series 3, Episode 1

info_outline
ANA Investigates Dysautonomia show art ANA Investigates Dysautonomia

ANA Investigates

Autonomic dysfunction often presents with subtle symptoms affecting multiple organ systems simultaneously. On this episode of ANA Investigates, we discuss bedside evaluation and advanced workup of dysautonomia and how to manage refractory symptoms. Featuring Safwan Jaradeh, MD, Professor of Neurology, Psychiatry and Behavioral Sciences and Director of the Autonomic Disorders Program at the Stanford Neuroscience Health Center & Megan Richie, MD, Associate Professor, UCSF. Series 2, Episode 11.

info_outline
ANA Investigates Central Nervous System Tumor Classification show art ANA Investigates Central Nervous System Tumor Classification

ANA Investigates

In July, the World Health Organization released its updated classification of Tumors of the Central Nervous System. The last update was in 2016. The update reflects the increasing role of molecular biomarkers in tumor characterization -- a change that has major implications for how we diagnose and treat patients with brain and spinal cord tumors. Joining us today to help us understand these changes are Drs. Lynne Taylor (University of Washington) & Douglas Ney (University of Colorado).

info_outline
 
More Episodes

Today, in recognition of Alzheimer’s and Brain Awareness month, we'll hear from Dr. David Holtzman, professor and chair of neurology at Washington University in St Louis. Dr. Holtzman's work has helped to clarify the relationship between Apolipoprotein E4, or apoE4, and Alzheimer's disease. He is also working to develop CSF biomarkers for Alzheimer's, and he has worked on the development of anti-amyloid beta and anti-tau antibodies for now being evaluated through clinical trials in patients with the disease. ANA’s education manager, Jen Hurley, spoke with Dr. Holtzman about the current state of research in biomarkers for Alzheimer’s disease. Dr. Holtzman wishes to disclose that he is a co-founder with equity in the company C2N Diagnostics, a biotech start up focusing on blood biomarkers for AD; he is on the Scientific advisory board of C2N Diagnostics and Denali Therapeutics, and consults for Genentech and Idorsia. Series 1, Episode 13